How SDI combines testing, tracking, treating and isolating to empower patients and providers
At SDI Labs, data, science and innovation are at the core of our work. Since the virus first appeared, we’ve been learning about it and focusing on the data, including what it means for our patients and their communities.
SDI Labs CEO Oz Mohiuddin and Medical Director Dr. David Haase have been at the forefront of our work. They’ve been following the latest research and studies about the virus, and how it behaves. Even before the COVID-19 pandemic, SDI Labs centered its work around identifying complex infectious diseases.
Leveraging their research, knowledge of infectious diseases and their individual expertise, Oz and Dr. Haase played integral roles in developing SDI’s comprehensive approach to COVID-19.
“Our approach is an end-to-end solution focused on patient centricity,” Oz said. It involves four key steps: test, track, treat, and isolate.
First, SDI Labs believes in testing 100% of the patient population to determine a baseline of who has an active SARS-CoV-2 infection and who does not. Then, SDI Labs uses a digital intake process to collect essential data that, in the event of a positive diagnosis, informs the provider and enables virus contact tracing.
“The tracking part is very important at the patient population level, especially with this virus and infectious diseases so that we can inform the doctors and public health agencies on how to control the spread,” Oz said. “We have built-in systems, data solutions, mobile systems, and cloud applications to help us do that because we are just not a lab. We are a technology company combined with a lab.”
Then, SDI Labs connects patients to telehealth providers and empowers physicians with accurate data to appropriately assess and triage the patient, and determine the best therapies and care.
“We are partnering with telehealth companies to give the right level of guidance and data so that the doctor can assess and triage the patient — who needs quarantine, who needs the next level of care — based on the data that we have on symptoms, underlying medical conditions, medication, and the test results,” Oz said.
Finally, SDI Labs encourages patients who are infected, think they might be, or came into contact with someone who was, to stay home and isolate in an effort to halt the spread within their community.
“The system is extremely important not only for the data, but the efficiency,” Oz said. Leveraging a systems approach, providers are able to treat the whole patient and figure out what is really happening. If a patient tests negative, but still has symptoms, they can be tested for co-infections. Or, if a patient has medical conditions that put them at high-risk, their test can be prioritized.
It is in using a thorough system of testing, tracking, treating, and isolating, that providers have all of the necessary information to make informed decisions with their patients. There are many different factors that contribute to a person’s health: their history, the medications they take, and any underlying health conditions. A comprehensive approach takes all of this information into account.
SDI leverages both the viral RT-PCR RNA and antibody tests
Currently, there are two main types of COVID-19 testing kits approved for clinical use, the viral RT-PCR RNA testing kit and the antibody testing kit. SDI offers both. SDI’s viral RT-PCR RNA test is one of only 37 molecular-based tests approved by the Food and Drug Administration (FDA) under Emergency Use Authorization (EUA). The antibody serology test is also FDA EUA approved.
The viral RT-PCR RNA test detects a current SARS-CoV-2 infection. It tests for SARS-CoV-2 genetic material, also known as RNA. If the viral RNA is detected, then the virus is present. Dr. Haase feels this is the most important test.
RNA testing detects SARS-CoV-2 genetic material to identify if a patient is infected. According to documents published by the United States Food and Drug Administration (FDA) and the World Health Organization (WHO), RNA tests are the first choice in the diagnosis of COVID-19.
Antibody testing uses a blood sample to detect two types of antibodies: IgM, which develop early on in an infection, and IgG, which are more likely to appear after an individual has recovered. Antibody tests can be used to supplement RNA tests, but should not be used as the sole basis for the diagnosis or exclusion of COVID-19, according to the CDC and the WHO.
“This test is fraught with more challenges because there are other coronaviruses outside of SARS-CoV-2. Sometimes these antibody tests can create a false positive test or maybe that individual doesn’t produce a lot of antibodies because they don’t have an intact immune system, then you would get a false negative response,” Dr. Haase said.
Combining the use of viral RT-PCR RNA tests and antibody tests allows patients to identify both if they are currently infected with COVID-19, and if they may have previously been infected.
With this information, patients have a better understanding of their health history. Meanwhile, employers are able to understand who is currently infected, who has been infected, and who hasn’t been. Based on that data, they’re able to make informed decisions about safe workplace re-entry.
“We do the viral RT-PCR RNA test to identify the current infection — whether the patient is currently infected or not,” Oz said. “If the patient is negative, if they are an employee, we evaluate their immunity to say whether they have developed antibodies to get back to work, to the greatest possibility with the mask and social distancing guidelines. That’s why we combine highly sensitive antibody testing with the wider testing of the viral RT-PCR RNA test.”